Our study demonstrated a remarkable increase of intratumoral LAMP3+ DCs aggregation in tumor lesions in neoadjuvant MPR tumor lesions, suggesting LAMP3+ DCs may contribute to the anti-tumor immune response of neoadjuvant chemoimmunotherapy. This evidence concerns the gene LAMP3 and neoplasm.